Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Multicenter prospective study to evaluate the efficacy of lenvatinib to achieve conversion surgery for initially unresectable hepatocellular carcinoma: LENS-HCC trial.
Authors
Masaharu Tada
Department of Gastroenterological Surgery, Hyogo College of Medicine, Nishinomiya Hyogo, Japan
Masaharu Tada , Akihiko Ichida , Junichi Arita , Etsuro Hatano , Susumu Eguchi , Akio Saiura , Hiroaki Nagano , Junichi Shindoh , Masaji Hashimoto , Nobuyuki Takemura , Kojiro Taura , Yoshihiro Sakamoto , Yu Takahashi , Yasuji Seyama , Yasuharu Sasaki , Kohei Uemura , Norihiro Kokudo , Kiyoshi Hasegawa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
jRCTs031190057
DOI
10.1200/JCO.2022.40.4_suppl.458
Abstract #
458
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy of lenvatinib (LEN) vs sorafenib (SOR) in the first-line (1L) treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC): A post hoc analysis of patients with nonviral etiology from REFLECT.
First Author: Ari David Baron
Poster
2021 ASCO Annual Meeting
The cost effectiveness of lenvatinib versus atezolizumab and bevacizumab or sorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in Canada.
First Author: David Trueman
Poster
2021 Gastrointestinal Cancers Symposium
Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients treated in United States clinical practices.
First Author: Amit G. Singal
Poster
2021 Gastrointestinal Cancers Symposium
Post hoc analysis in patients (pts) with unresectable hepatocellular carcinoma (uHCC) who progressed to Child-Pugh B (CPB) liver function in the phase III REFLECT study of lenvatinib (LEN).
First Author: Jasmine Huynh